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Background: Patients with locally advanced and high-risk prostate cancer (LAPC) are prone to experience
biochemical recurrence despite radical prostatectomy (RP). We evaluated feasibility, safety and activity of a
neoadjuvant chemohormonal therapy (NCHT) with 3-weekly full dose docetaxel and complete androgen
blockade (CAB) in locally advanced and high-risk prostate cancer patients (LAPC) undergoing RP.
Methods: Patients (n = 30) were selected by Kattans’ preoperative score and received trimestral buserelin
9,45 mg, bicalutamide 50 mg/day and 3 cycles docetaxel (75 mg/m2) followed by RP. Primary endpoints were
biochemical (PSA) and local downstaging. Secondary endpoints included toxicity and operability assessments,
pathological complete response (pCR), time to PSA progression, 5-year biochemical recurrence free survival
(bRFS) and overall survival (OS).
Results: Median baseline PSA was 25.8 ng/ml (2.1–293), and the predicted probability of 5-year bRFS was 10%
(0–55). NCHT induced PSA-reduction was 97.3% (81.3-99.9%; p < 0.001) and post-RP 96.7% of patients were
therapy responders, with undetectable PSA-values. Post- vs. pretreatment MRI indicated a median tumor volume
reduction of 46.4% (−31.3-82.8; p < 0.001). A pathological downstaging was observed in 48.3%. Severe hematologic
toxicities (≥CTC3) were frequent with 53.8% leucopenia, 90% neutropenia and 13.3% febrile neutropenia. RP was
performed in all patients. While resectability was hindered in 26.7%, continence was achieved in 96.7%. Pathologic
analyses revealed no pCR. Lymph node- and extracapsular involvement was observed in 36.7% and 56.7% with
33.3% positive surgical margins. After a median of 48.6 (19.9-87.8) months, 55.2% of therapy responders
experienced PSA-recurrence. The estimated median time to PSA-progression was 38.6 months (95%CI 30.9-46.4)
and 85.3 months (95%CI 39.3–131.3) for OS. The 5-year bRFS was improved to 40%, but limiting for interpretation
adjuvant treatment was individualized.
Conclusions: NCHT is feasible despite high hematotoxicity, with excellent functional results. Significant
downstaging was observed without pCR. NCHT seems to improve the cohort adjusted 5-year bRFS, but clinical
value needs further investigation in randomized trials.
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Prostate specific antigen (ng/ml)
Median (mean) 25.8 (43.2)
Range 2.1-293.0











Median (mean) 172 (171)
Range 125-200
Probability of 5-year bRFS (%)
Median (mean) 10 (10)
Range 0-55
Abbreviation: bRFS, biochemical recurrence free survival.
Thalgott et al. Journal of Hematology & Oncology 2014, 7:20 Page 2 of 9
http://www.jhoonline.org/content/7/1/20Background
Patients with locally advanced and high-risk prostate can-
cer (LAPC) are prone to experience biochemical recur-
rence despite curative-intended radical prostatectomy
(RP). Predictor variables are PSA-value, clinical stage and
Gleason score [1,2]. In order to improve clinical outcome,
neoadjuvant regimens combined with curative treatment
options are investigated [3]. In contrast to approved an-
drogen deprivation therapies (ADT) concomitant to exter-
nal beam radiation, there is no standardized systemic
perioperative regimen for LAPC patients undergoing RP
[3-5]. Presurgical ADT induces downstaging with reduced
positive surgical margins and lymph node metastases but
fails to improve survival or to induce relevant pathological
complete response (pCR) rates [6,7].
In castration-resistant prostate cancer patients (CRPC),
docetaxel chemotherapy (D) is standard of care due to
prolonged survival in randomized phase III trials [8-11].
Subsequently, docetaxel was investigated for neoadjuvant
treatment in patients with locally advanced PC. Similar to
neoadjuvant ADT, preoperative docetaxel monotherapy
did not improve survival and no pCR was observed, des-
pite PSA-reduction and local downstaging [3,12-14].
Since androgen-dependent and -independent cell sub-
populations may coexist, neoadjuvant strategies combining
docetaxel and complete androgen blockade (CAB) were in-
vestigated, still resulting in deficient pCR rates of 3-6%
[15,16]. In favor of reduced morbidity, the latter trials used
weekly regimens of docetaxel, albeit 3-weekly administered
docetaxel demonstrated superior clinical efficacy in com-
parison to weekly schedules, in CRPC patients [8,9].
The combination of CAB with a 3-weekly full dose regi-
men of docetaxel (75 mg/m2), over a period of 3 cycles
(9 weeks), may exhibit superior activity to downstage tu-
mors and improve oncological outcome. Therefore, we
prospectively determined feasibility, safety and activity of
this presurgical short-term combination therapy in 30
LAPC patients undergoing RP.
Results
Patient characteristics
The clinical patient characteristics are outlined in Table 1.
Between July 2005 and February 2010, 30 patients were
enrolled. Median pretreatment values were 25.8 ng/ml for
PSA, 7 for biopsy Gleason score, cT3b for clinical stage
and 68 years for age. According to Kattan’s nomogram,
the median probability of bRFS was 10% (range 0–55) [1].
Neoadjuvant treatment and toxicity profile
Overall 86 cycles of docetaxel were administered and 27
(90%) patients completed all 3 cycles. Three patients
(10%) discontinued NCHT; one withdrew consent after
one cycle, and two interrupted due to NCHT-unrelated
severe AE (lumbar disk herniation; exacerbating peripheralarterial occlusion disease (PAOD)) after two cycles of do-
cetaxel. Bicalutamide was continued up to RP except for
the patient with PAOD. Dose reductions of docetaxel were
necessary in two patients (6.7%) and a treatment deferral
in one patient (3.3%). Adverse events occurring in ≥10%
of patients are presented in Table 2. Grade 3/4 non-
hematologic toxicities were pneumonia (3.3%) and
hyperglycemia (3.3%). Grade 3/4 hematologic toxicities
were leucopenia in 53.8% (n = 14) and neutropenia in 90%
(n = 18), in patients amenable for hematologic analyses one
week after docetaxel administration. Febrile neutropenia
was observed in 13.3%. Late toxicity assessments after a
median follow up (FU) of 48.6 months (range 14.1-87.8)
revealed one case (3.3%) of lower neuropathy (Grade 1).
Second malignancies were observed in 2 cases (6.7%), one
patient with bronchial carcinoma and another patient with
bladder cancer, who received adjuvant radiation therapy.
Surgical and pathological outcome
All patients (n = 30) underwent RP with histopatho-
logical analyses after a median interval of 70 days from
Table 2 Adverse events, according to CTC grades, occurring in >10% of patients
Toxicity Patients Grade 1 Grade 2 Grade 3 Grade 4
n n (%) n (%) n (%) n (%)
Alopecia 30 18 (60.0) 11 (36.7) 0 0
Fatigue and asthenia 30 14 (46.7) 14 (46.7) 0 0
Sensory neuropathy 30 9 (30.0) 4 (13.3) 0 0
Edema 30 16 (53.3) 0 0 0
Nausea and vomiting 30 10 (30.0) 0 0 0
Diarrhea 30 6 (20.0) 1 (3.3) 0 0
Constipation 30 4 (13.3) 0 0 0
Stomatitis 30 10 (33.3) 3 (10.0) 0 0
Febrile neutropenia 30 0 0 3 (10.0) 1 (3.3)
Skin rash 30 6 (20.0) 0 0 0
Arthralgia and myalgia 30 4 (13.3) 1 (3.3) 0 0
Perspiration 30 8 (26.7) 1 (3.3) 0 0
Dysgeusia 30 15 (50.0) 5 (16.7) 0 0
Nail changes 30 18 (60.0) 0 0 0
Hot flush 30 12 (40.0) 2 (6.7) 0 0
Depressive symptoms 30 8 (26.7) 1 (3.3) 0 0
Insomnia 30 8 (26.7) 0 0 0
Dyspepsia and abdominal pain 30 6 (20.0) 0 0 0
Sore throat and dysphagia 30 5 (16.7) 2 (6.7) 0 0
Chill 30 4 (13.3) 0 0 0
Increased urea 28 18 (64.3) 0 0 0
Increased potassium 30 4 (13.3) 0 0 0
Hypoproteinemia 23 4 (17.4) 0 0 0
Increased GGT 27 4 (14.8) 1 (3.7) 0 0
Increased GPT 27 4 (14.8) 0 0 0
Increased LDH 22 20 (90.9) 0 0 0
Anemia, day 21 25# 12 (48.0) 0 0 0
Anemia, day 7 21# 16 (76.2) 0 0 0
Leucopenia, day 7 26 5 (19.2) 4 (15.4) 10 (38.5) 4 (15.4)
Neutropenia, day 7 20 0 1 (5.0) 4 (20.0) 14 (70.0)
Abbreviations: CTC, Common Terminology Criteria for Adverse Events; GGT, Gamma-Glutamyl-Transferase; GPT, Glutamat-Pyruvat-Transaminase; LDH, Lactate
Dehydrogenase; #, five patients excluded due to preexisting anemia at inclusion.
Thalgott et al. Journal of Hematology & Oncology 2014, 7:20 Page 3 of 9
http://www.jhoonline.org/content/7/1/20day 1 (range 61–143). Median removed lymph nodes
were 16 (range 5–39). Surgical variables are depicted in
Table 3 and pathological results in Table 4. Resectability
was hindered due to periprostatic fibrosis in 23.3% and
to increased vulnerability with increased diffuse bleed-
ing in 3.3%. In case of periprostatic fibrosis the identifi-
cation and dissection of the appropriate surgical layers
was more difficult, when compared to not pretreated
patients. Early re-interventions were required due to
symptomatic lymphoceles (20%), hydronephrosis (3.3%)
and bleeding (3.3%). Late events were urethral strictures
(6.7%). Pathological analyses revealed extracapsular ex-
tension in 56.5% with positive surgical margins (R1) in33.3% (n = 10) and lymph node involvement (pN1) in
36.7% of patients (n = 11).
Long time functional outcome, following a median of
48.6 months (range 14.1-87.8), revealed continence in
96.7%. Before treatment 86.7% (n = 26) patients were po-
tent. After RP 15.4% had spontaneous erections (E3-E4),
11.5% were potent with erection aids and 19.2% had tu-
mescence sufficient for sexual activity but not for vaginal
penetration (E1-E2).
Clinical activity
All patients (n = 30) demonstrated a PSA reduction fol-
lowing NCHT with a median decline of 97.3% (range
Table 3 Surgical variables and complications
Variable Value
Patients with radical prostatectomy, n 30




Median (mean) 195 (208.7)
Range 140-333
Nerve sparing, n (%)
Bilateral 6 (20.0)
Unilateral 3 (10.0)
Not possible 21 (70.0)
Intraoperative blood loss, ml
Median (mean) 600 (769.2)
Range 100-2600
No. of transfused blood units, n
Median (mean) 0 (0.9)
Range 0-5
Complications, needing intervention, n (%)§
Symptomatic pelvic hematoma 1 (3.3)
Hydronephrosis 1 (3.3)
Lymphocele 6 (20.0)
Complications in≥ 10% of cases, n (%)§
Joint pain 3 (10.0)
Venous/pulmonary thromboembolism 5 (16.7)
Time to catheter removal, days
Median (mean) 8 (13.1)
Range 7-47
Continence, no. of pads, n (%)*
0 29 (96.7)
≥1 1 (3.3)
Erectile function (n = 26), n (%)*
Potent (E 3–4) 4 (15.4)
Potent with erection aids (E 3–4) 3 (11.5)
Tumescence (E 1–2) 5 (19.2)
Impotence (E 0) 14 (53.9)
Abbreviations: #skin incision to skin suture; §within 4 weeks from surgery;
*after a median follow up of 48.6 months (range 14.1-87.8).
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observed in 100% and a complete response in 13.3%. After
RP 96.7% of patients were therapy responders with un-
detectable PSA-values.
Downstaging of the clinical T-stage, indicated by MRI,
was observed in 32% of 25 evaluable patients (cT3a to
cT2 n = 3; cT3b to cT2 n = 2; cT3b to cT3a n = 2; cT4 to
cT3a n = 1), without upstaging. Prostate volume wasreduced in all cases with a significant median decrease of
37.1% (range 17.2-68.5%; p < 0.001). Similarly a significant
median tumor volume reduction of 46.4% (range −31.3-
82.8%; p < 0.001) was observed in 95.7% (n = 22) of patients
harboring measurable tumors, while one progressed (4.3%).
Pathological downstaging, comparing initial T-stages on
MRI (n = 29) with histopathological stages revealed down-
staging in 48.3% (cT3a to pT2 n = 2; cT3b to pT2 n = 10;
cT3b to pT3a n = 1; cT4 to pT3b n = 1) and upstaging in
13.8% (cT2 to pT3b n = 1; cT3a to pT3b n = 3). Histopatho-
logical analyses revealed no pathological complete response
(pCR), and only one (3.3%) pathological minimal residual
disease (pMRD) with a tumor volume of <5%.
Time to PSA progression and overall survival
After a median FU of 48.6 months (range 19.9-87.8), of the
29 treatment responders 55.2% experienced a biochemical
progression. The estimated median time to PSA progres-
sion was 38.6 months (95% CI 30.9-46.4) with a 5-year bio-
chemical recurrence free survival of 40% (Figure 2a).
Adjuvant ADT was administered in 7 (23.3%) patients
over a mean of 19 months (range 11–28) due to patho-
logical R1N1 (n = 2) or R0N1 (n = 5) stages. Adjuvant radi-
ation therapy (RT) was performed in 3 (10%) patients due
to positive surgical margins without lymph node involve-
ment (R1N0). No adjuvant RT was performed in 3 patients
despite a R1N0 stage in favor a deferred RT in case of bio-
chemical recurrence and in 4 patients with a R1N1 stage.
At the time of this analysis 26 (86.7%) patients were still
alive. Two patients (6.7%) experienced a PC related death.
The estimated median OS in the complete cohort was
85.3 months (95%CI 39.3–131.3) (Figure 2b).
Discussion
We investigated a short-term neoadjuvant therapy with 3-
weekly full dose docetaxel (D), combined with CAB in
LAPC patients undergoing RP. Although presurgical
docetaxel-based regimens were investigated earlier, FU
data are mostly short-term (Table 4). In addition, investi-
gating D +CAB, weekly docetaxel schedules were used,
potentially exhibiting inferior clinical activity [8,9,15,16].
Further, a high prognostic variability was observed within
and across cohorts due to study accrual following D’Ami-
co’s criteria [2,3,15,17]. To our knowledge we are the first
to present a D ±ADT treated cohort recruited according
to Kattan’s nomogram, that allows for selection of equable
high-risk populations [1,3,17]. Thus our cohort displays a
probability of 5-year bRFS of only 10%.
With respect to non-hematologic toxicities, we ob-
served the known profile of AE during palliative or neo-
adjuvant D ± ADT. The incidence of severe AE was low
(7%) when compared to weekly D monotherapy (21-
53%) or weekly D + CAB (21-26%) [12,13,15,16]. In con-
trast severe hematologic toxicities were frequent with
Table 4 Pathological and oncological results in trials using presurgical docetaxel ± hormonal therapy
Therapy Docetaxel + Hormonal Therapy Docetaxel – Single Treatment
Author year Current
series







































































50 mg/d (4 weeks)
n.d. n.d. n.d. n.d. n.d.
Estramustine n.d. 1120 mg/d
(6 weeks)







Therapy-weeks 9 6 12 12 12 24 16-60 18 6 24 6
pCR (%) 0 11.1 0 6 0 3.1 5 0 0 0 0
pMRD (%) 3.33 n.d. n.d. 6 n.d. 25 31.6* n.d. n.d. n.d. 7.14
iPSA, median,
range (ng/ml)
25.8 25.8 22.3 9.7 21.2 10.8 41 16.1 n.d. n.d. 12
2.1-293 5.1-45.1 0.3-255 0.6-90.8 3.2-71.6 1.6-65.6 n.d. 2.4-175 2.5-43.3
iGl. sc. ≥7 (%) 90 87.4 100 95 n.d. 91 86 96 93 75 94
≥cT3 (%) 93.3 43.8 27 28 64 39 86 25 17.8 16 27
≥pT3 (%) 56.5 38.9 72.7 37 36.4 44 42 70 82.1 62 89
SVI (%) 53.3 11.1 45.5 n.d. 40.9 22 37 60 39.3 50 32
R0 (%) 66.7 100 63.6 64.7 72.7 73 74 70 75 n.d. 96
pN1 (%) 36.7 22.2 n.d. 3.9 18.1 6 21 10 14.3 0 14
FU, median,
range (months)
48.6 18 24 35 23.6 42.7 53 13.1 49.5 26.5 23
20-88 1-49 n.d. 23-47 12-55 26-66 30-64 9-18 23-72 4.5-40 1.5-36
Recur. Pts. (%) 55.2 22.2 55 35.1 45.4 30.0 58.0 29.0 57.0 63.2 29.0
Abbreviations: CSOS, cancer specific overall survival; cT3, clinical stage T3 with capsular penetration; pT3, pathological stage T3 with capsular penetration; D, docetaxel; FU, follow up; iGl. sc., initial Gleason score; iPSA,
initial prostate-specific antigen; LHRH, luteinizing hormone releasing hormone; n.a., not applicable; n.d., not done; pN1, pathological lymph node involvement; pCR, pathological complete response; pMRD, pathological
minimal residual disease with <5% PC in surgical specimens; *, pMRD with <10% PC in surgical specimens; q, treatment interval of 7 or 21 days; R0, negative surgical resection margin; RP, radical prostatectomy; Recur.



















Figure 1 Boxplot diagram showing prostate specific antigen (PSA)-response by treatment interval in the complete cohort of patients; extreme
values (n = 3) at screening are not presented for graphing reasons; Abbreviations: o, outliers; *, extreme outliers; RP, radical prostatectomy.
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http://www.jhoonline.org/content/7/1/20leucopenia in 54% and neutropenia in 90%, when analyzed
one week after D administration. Thus hematotoxicity was
increased compared to weekly D monotherapy (0-14%)
and D + CAB (0-15%) [12,13,15,16]. Our increased hema-
totoxicity might be caused by the 3-weekly full dose doce-
taxel regimen and especially by blood collection at the
nadir of leucopenia.
Surgical variables are in accordance with literature. Re-
sectability was partly hindered due to callosity as reported
earlier for neoadjuvant docetaxel or CAB [7,12,13,15-19].
The rate of positive surgical margins in our series reflects
the midrange of earlier published trials (Table 4). With re-
spect to functional outcome, 97% of our patients are con-
tinent, similar to other trials reporting 89-95% continence
rates [7,12,13]. Erectile function assessments revealed sex-
ual activity in 46% of our patients, whereas 15.4% returned
to baseline potency. Regrettably the majority did not try
erection aids. Overall, despite explicit locally advanced
stages our patients experienced excellent continence and
sexual activity after RP. Comparing the excellent contin-
ence rates across neoadjuvant studies, to the results from
the CaPSURE study with 63% continence and 20% po-
tency after sole RP, the magnitude of presurgical treatment
might be the amelioration of the functional outcome in
patients with locally advanced stages treated with RP [20].
Several trials used a pCR rate of 10-40% as primary
endpoint, but failed [7,13,15-17]. Using combinations of
weekly D + CAB a pCR rate of 3-6% and pMRD rates of6-25% were demonstrated [15,16]. In our study only one
patient presented a pMRD (3%) and none a pCR. This
was surprising as we used the potentially more active 3-
weekly docetaxel regime. The superior results by Chi
et al. might be a consequence of prolonged treatment of
24 weeks [16]. Overall neoadjuvant regimens with D ±
CAB seem unable to achieve relevant pCR or pMRD
rates [17]. A marginal improvement was observed by
adding estramustine phosphate (EMP) to D + ADT
(Table 4).
With respect to downstaging we observed a partial
PSA response in 100% and a complete PSA response in
13%. The PSA-value reduction was 97%, similar to
weekly D + CAB or D + EMP, but superior to docetaxel
monotherapy with 64% PSA-decline and 24% partial re-
sponse [12,13,15,16,21]. In addition we observed local
clinical downstaging with tumor volume reduction in
96% and T-stage shift in 32%. The overall tumor volume
decrease was 46%, thus being superior to D monother-
apy with 26%, whereas our T-stage reduction rate is
similar to ADT alone with 30% [13,22]. Finally we ob-
served pathological downstaging in 48%, which was su-
perior to ADT alone (15%) and comparable to D +
ADT + EMP achieving 42% [7,22]. In summary, our re-
sults attained the primary endpoint with a downstaging
proportion of >40% for PSA decrement, tumor volume
decrease and pathological downstaging but not for
clinical T-stage shift.
ab
Figure 2 Kaplan–Meier plot for a. biochemical recurrence free
survival (bRFS), in patients defined as therapy responders
(n = 29). b. overall survival (OS) in the complete cohort
of patients.
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currence rates are rare. Using D +ADT + EMP a recur-
rence rate of 58% was observed after a FU of 53 months
[7]. Similarly D monotherapy revealed a recurrence rate of
57% after a median FU of 50 months, equal to a matched
control group [14]. In our trial the biochemical recurrence
rate was 55% after a FU of 49 months. Thus our results
are similar to the cited studies, although comparability is
hindered due to different inclusion criteria. The 5-year
bRFS in our cohort was increased to 40%, when comparedto the predicted median of 10% [1]. However, the inter-
pretation of our results is limited due to individualized ad-
juvant strategies. Further, interesting results were
presented following weekly D +CAB with a recurrence
rate of only 30% after a moderate briefer FU of 43 months
[16]. The difference with our results might be a conse-
quence of the longer treatment interval as well as patient
selection with lower PSA-values, fewer ECE and lymph
node involvement (Table 4).
Although our trial gives additional clinical information
and confirms significant clinical activity of neoadjuvant D +
CAB, our study has certain limitations especially with re-
spect to bRFS. Adjuvant treatment was not uniformly de-
fined. This is in accordance with literature, but contrasts
with other trials that excluded adjuvant therapy until pro-
gression [7,12,13,15,16,23]. However due to underpowered
trials, limited FU-times, variations on post-surgical manage-
ment, lack of randomization and comparability, the ideal
neoadjuvant approach is not yet defined [15,17]. Maybe the
randomized phase III trial CALGB 90203 comparing neoad-
juvant D +ADT vs. RP alone, with the primary endpoint of
3-year biochemical progression-free survival, is capable to
answer the remaining questions. But to the best of our
knowledge results are not on short call [24].
Conclusions
To our knowledge we are the first to present a long time
FU of a phase II trial, investigating a short-term neoadjuvant
therapy with 3-weekly full dose docetaxel, combined with
CAB in locally advanced and high-risk PC patients sched-
uled for RP. The regimen is feasible, despite a high rate of
severe neutropenia and leucopenia. Significant clinical activ-
ity was observed, despite absence of pCR. Surgical variables
revealed an excellent functional outcome. Finally a precar-
iously 30% improvement of the 5-year bRFS was achieved.
Methods
This single-center non-randomised phase II trial was con-
ducted at the Department of Urology, Klinikum rechts der
Isar, Technische Universität München. The study was ap-
proved by the institutional review board and the regulatory
authorities and was performed in accordance with the eth-
ical standards of the Declaration of Helsinki. All subjects
gave written informed consent. Main eligibility criteria were
adenocarcinoma of the prostate, absence of metastatic dis-
ease and a biochemical recurrence risk of >40% within
5 years, according to Kattan’s preoperative nomogram [1].
Primary objectives were downstaging effects, reflected
by PSA-value decrement and local tumor reduction by
clinical and pathological criteria. Secondary objectives
were the pCR and pathological minimal residual disease
(pMRD) rate, the toxicity profile and operability, along
with time to PSA progression, 5-year biochemical recur-
rence free survival (bRFS) and overall survival (OS).
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Presurgical treatment consisted of CAB comprising bicaluta-
mide 50 mg/day p.o. starting day 1 until the day before RP
with trimestral buserelin 9.45 mg s.c. on day 3 and three cy-
cles of docetaxel chemotherapy (75 mg/m2) on days 8, 29
and 50 in combination with prednisolone 10 mg/day p.o.
starting on day 9. Dexamethasone (8 mg p.o.) was adminis-
tered 12 hours before and after docetaxel as well as 60 min
before. A dose reduction of docetaxel to 60 mg/m2 and a
treatment deferral of 21 days were allowed. All patients
underwent open retropubic RP including extended bilateral
pelvic lymph node dissection up to the aorta. Adjuvant radi-
ation and hormonal therapies were individualized according
to pathological results [13,23]. NCHT was aborted in case of
unacceptable toxicities, progression or on patients’ request.
Staging and clinical activity
Tumor staging included digital rectal examination, abdom-
inal and transrectal ultrasound, chest X-ray, bone- and
computed tomography scans (CT) or magnetic resonance
imaging (MRI) of the pelvis. Pelvic lymph nodes were con-
sidered non-metastatic if the maximum diameter did not
exceed 1.5 cm. Local clinical downstaging was assessed by
MRI of the prostate with endorectal coil (1.5 T, Magnetom
Avanto, Siemens, Germany) before and after NCHT. T2-
weighted sequences in three planes, axial T1-weighted and
a dynamic-contrast-enhanced sequence were analyzed in-
dependently by a board certified radiologist. Median pros-
tate and tumor volumes were calculated [13,25-27]. Tumor
volume was determined by measuring the maximum tumor
area in the axial plane and the longest cranio-caudal diam-
eter. In case of multiple tumor nodules, each was measured
separately. Pathologic specimens were classified according
to the “Union international contre le cancer” version 2002.
Gleason grading is not valid following NCHT, consequently
it was not determined [7,15]. The absence of PC in the
histo-pathological sections was defined as pCR and tumor
volumes <5% as pMRD [15]. In addition, pathologic down-
staging, comparing initial stages on MRI with histopatho-
logical stages, was analyzed [7,13,22]. PSA response was
assessed before RP and latest 3 months post-RP. Before RP,
a PSA reduction of >50% indicated partial response and
PSA-levels <0.2 ng/ml a complete response [15]. After RP,
patients with PSA-values <0.07 ng/ml were deemed therapy
responders. Biochemical recurrence was defined by two
PSA increases >0.2 ng/ml [28].
Surgical variables were recorded implying the functional
outcome. Continence was defined as the use of no pads
and erectile function using the erection hardness score
(E0-E4) [7,29]. Adverse events (AE) were registered ac-
cording to Common Terminology Criteria (CTCAE 3.0),
including dose reductions and treatment deferrals. Add-
itional hematologic analyses were performed one week
after docetaxel application.Statistical analysis
This trial was conducted as an intent to treat approach
[30]. Sample sizes were calculated using the software N-
Query version 7.0. With a sample size of 24 patients, a
one-sided 97.5% confidence interval for the downstaging
proportion, using the large sample normal approximation,
will extend 20% from the observed proportion for an ex-
pected proportion of 40%. Analyses were performed using
SPSS version 20 (SPSS Inc., Chicago, IL, USA). Changes in
continuous measures over time were determined using
the Wilcoxon signed-rank test and linear trend analyses
using the Kruskal-Wallis test. Applying a Bonferroni cor-
rection, a p-value of <0.025 was considered statistically
significant. Estimates of survival were analyzed using the
Kaplan-Meier method. OS was defined as the elapsed time
from screening to death and time to PSA progression as
time from the first study treatment to biochemical pro-
gression [30].
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